Exchange: NASDAQ·Updated 07:30 PM EST

STRO News

News
all
press releases
Sutro Biopharma Q4 Earnings Forecast Lifted by HC Wainwright
Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Investment analysts at HC Wainwright increased their Q4 2026 earnings estimates for shares of Sutro Biopharma in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnin...
MarketBeat
Sutro Biopharma Q4 Earnings Forecast Lifted by HC Wainwright
Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Investment analysts at HC Wainwright increased their Q4 2026 earnings estimates for shares of Sutro Biopharma in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnin...
MarketBeat
More News
Wall Street Zen raised shares of Sutro Biopharma from a "strong sell" rating to a "sell" rating in a research note on Monday...
MarketBeat
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of -11.94% and -49.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
The heavy selling pressure might have exhausted for Sutro Biopharma (STRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Sutro Biopharma (STRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Axsome (AXSM) delivered earnings and revenue surprises of +63.77% and +5.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
H.C. Wainwright believes the selloff largely reflects an overreaction to the limited efficacy details disclosed for STRO-004 by the company.
Stocktwits
Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.read more...
Benzinga
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.